Patient Demographics and Clinical Characteristics
| Characteristic | HER2+ (n = 11) | HER2− (n = 7) |
| Median age (y) | 59 y (age range, 35–75 y) | 61 y (age range, 40–71 y) |
| Hormone receptor and HER2 status of recurrent disease | ||
| ER and PR receptors | ||
| ER- and/or PR-positive | 6 | |
| ER- and PR-negative | 5 | |
| HER2 | ||
| IHC1+ | ||
| IHC2+ | 3 | |
| IHC3+ | 8 | |
| Prior HER2-directed therapy | ||
| None | 3 | |
| Trastuzumab for metastasis | 8 (79 d–36 mo) | |
| Sites of metastatic disease measured for SUVmax | ||
| Bone | 24 | |
| Lymph nodes | 23 | |
| Liver | 6 | |
| Lung | 6 | |
| Other* | 2 | |
| Breast/chest wall† | 5 | |
| Tumor volume (cm3)‡ | ||
| Mean | 5.8 | |
| SE | 0.9 |
↵* Pulmonary effusion (HER2+) or body wall outside breast region.
↵† Breast or chest wall adjacent to breast.
↵‡ Volume within isocontour of 18F-FDG tumor image approximately matching boundary of CT correlate.
HER2 = human epidermal growth factor receptor 2; ER = estrogen receptor; PR = progesterone receptor; IHC = immunohistochemistry.